Literature DB >> 8705906

The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research.

P H Watson1, L Snell, M Parisien.   

Abstract

The NCIC-Manitoba Breast Tumor Bank is one of several tumour banks that have been established through the Molecular Epidemiology Program of the National Cancer Institute of Canada (NCIC). The NCIC-Manitoba Breast Tumor Bank is an example of one model developed to facilitate research designed to translate the findings of basic science into information useful in the clinical arena. The tumour bank's mandate is to provide a national resource that consists of a preassembled dataset of matched samples of paraffin-embedded and frozen tumour tissue with corresponding pathological and clinical data. In the first 3 years the tumour bank has accrued data and samples from over 1800 cases of breast cancer and has provided support for 20 research projects across Canada and the United States.

Entities:  

Mesh:

Year:  1996        PMID: 8705906      PMCID: PMC1487994     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  6 in total

1.  Role of the frozen tissue bank in molecular pathology.

Authors:  S P Naber; L L Smith; H J Wolfe
Journal:  Diagn Mol Pathol       Date:  1992-03

Review 2.  Colorectal cancer and the intersection between basic and clinical research.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

3.  The genetic origins of neoplasia.

Authors:  A J Levine
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

Review 4.  Molecular markers in cancer: can we make better predictions?

Authors:  D Sidransky
Journal:  Int J Cancer       Date:  1995-02-20       Impact factor: 7.396

5.  The Cooperative Human Tissue Network. An update.

Authors:  V A LiVolsi; K P Clausen; W Grizzle; W Newton; T G Pretlow; R Aamodt
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

6.  Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected].

Authors:  S E Kern; E R Fearon; K W Tersmette; J P Enterline; M Leppert; Y Nakamura; R White; B Vogelstein; S R Hamilton
Journal:  JAMA       Date:  1989-06-02       Impact factor: 56.272

  6 in total
  19 in total

1.  Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.

Authors:  A Huang; E R Leygue; L Snell; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.

Authors:  Mariam Al-Dhaheri; Jiacai Wu; Georgios P Skliris; Jun Li; Ken Higashimato; Yidan Wang; Kevin P White; Paul Lambert; Yuerong Zhu; Leigh Murphy; Wei Xu
Journal:  Cancer Res       Date:  2011-01-31       Impact factor: 12.701

3.  Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen.

Authors:  Georgios P Skliris; Zoann Nugent; Peter H Watson; Leigh C Murphy
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

4.  Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype.

Authors:  Anne A Blanchard; George P Skliris; Peter H Watson; Leigh C Murphy; Carla Penner; Ladislav Tomes; Tamara L Young; Etienne Leygue; Yvonne Myal
Journal:  Virchows Arch       Date:  2009-04-23       Impact factor: 4.064

5.  Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas.

Authors:  George P Skliris; Brian G Rowan; Mariam Al-Dhaheri; Christopher Williams; Sandy Troup; Sanela Begic; Michelle Parisien; Peter H Watson; Leigh C Murphy
Journal:  Breast Cancer Res Treat       Date:  2008-12-23       Impact factor: 4.872

6.  Lack of functional TSLP receptors mitigates Th2 polarization and the establishment and growth of 4T1 primary breast tumours but has different effects on tumour quantities in the lung and brain.

Authors:  R B Erdmann; J G Gartner; W J Leonard; C A Ellison
Journal:  Scand J Immunol       Date:  2013-11       Impact factor: 3.487

7.  Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer.

Authors:  E P Booy; E S Henson; S B Gibson
Journal:  Oncogene       Date:  2011-01-24       Impact factor: 9.867

8.  Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Authors:  Charlton Cooper; Jimin Guo; Yi Yan; Shilpa Chooniedass-Kothari; Florent Hube; Mohammad K Hamedani; Leigh C Murphy; Yvonne Myal; Etienne Leygue
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

9.  Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

Authors:  Yi Yan; George P Skliris; Carla Penner; Shilpa Chooniedass-Kothari; Charlton Cooper; Zoann Nugent; Anne Blanchard; Peter H Watson; Yvonne Myal; Leigh C Murphy; Etienne Leygue
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression.

Authors:  Syed M Ahmed; Brigitte L Thériault; Maruti Uppalapati; Catherine W N Chiu; Brenda L Gallie; Sachdev S Sidhu; Stéphane Angers
Journal:  J Cell Biol       Date:  2012-12-03       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.